Merck and Moderna’s personalized mRNA vaccine, intismeran autogene, for resected high-risk melanoma—the deadliest skin cancer—drove recent sentiment after October 22 Phase 3 INTerpath-001 results showed a 42% reduction in recurrence or death risk versus Keytruda alone in 1,137 patients. The individualized neoantigen therapy, built from each patient’s tumor sequencing and leveraging the same mRNA platform as COVID vaccines, met recurrence-free and distant metastasis-free survival endpoints, prompting immediate regulatory engagement. Analysts view this as the first positive late-stage readout for such an approach and project possible FDA filing momentum into 2027, though overall survival data remain pending and timelines can shift with manufacturing scale-up or additional safety reviews. Competitive positioning against other immunotherapy combinations and ongoing trials in lung and pancreatic cancers add further context for approval odds.